April 3, 2018 Our latest publication on Bioprocess Online, February 23, 2018
Source: GE Healthcare Life Sciences
As biopharma companies develop growing numbers of therapeutic proteins and drug budgets are squeezed worldwide, there is an increasing pressure on manufacturers to find more efficient production processes. To reach this goal, Rentschler Biopharma is using an approach called "smart bioprocessing" to create scalable manufacturing processes rapidly and efficiently.
The drivers of manufacturing therapeutic proteins are upstream productivity, protein quality, and overall cost. The aim of smart bioprocessing is to use bioinformatics, lab-scale processing, and analytics to create better process designs that can be verified before they are scaled up to clinical trial and commercial scale production.
The end goal is to generate a robust and reproducible cGMP-ready process that meets the criteria for overall yield, achieves the critical quality attributes, and creates a final downstream processing specification ready to scale up for production.
You will find the full article here.
Rentschler Biopharma SE
Dr. Latika Bhonsle-Deeng
Senior Director Corporate Communication